Healthcare / BiotechnologyNasdaqCM
$2.70
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-7.2M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$91M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-72.1%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-10.9M · FCF $-7.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | — | $210000.00 | — | $512000.00 | — | $250000.00 | $1.1M | $362500.00 | $300000.00 | $9.3M | $3.7M | $388850.00 | $940010.00 | $1.0M | $730675.00 |
| Net Income | $-10.9M | $-10.9M | $-12.6M | $-9.8M | $-13.6M | $-13.0M | $-10.0M | $-11.6M | $-14.0M | $-5.0M | $-5.0M | $-1.4M | $-9.6M | $-10.1M | $-4.3M | $-7.4M | $-5.2M |
| EBITDA | $-11.7M | $-11.7M | $-13.8M | $-11.0M | $-13.8M | — | — | — | $-14.3M | $-6.0M | $-4.5M | $-932244.00 | — | — | $-4.1M | $-5.0M | — |
| EPS | -0.34 | -0.34 | -0.39 | -0.32 | -0.45 | -0.45 | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | 23.3% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | -5243.3% | — | -2565.6% | — | -4756.0% | -1284.4% | -1676.0% | -1503.0% | -10.2% | -137.5% | -2036.2% | -439.8% | -501.2% | -718.3% |
| Net Margin | — | — | — | -4671.9% | — | -2530.1% | — | -4658.8% | -1258.1% | -1381.8% | -1672.1% | -14.9% | -261.9% | -2592.3% | -452.4% | -735.5% | -708.3% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | — | — | — | — | — | 0.07 | — | — | — | — | — |
| Current Ratio | 12.18 | 12.18 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-7.2M | $-7.2M | $-7.3M | $-6.2M | $-6.5M | — | $-6.2M | $-4.9M | $-4.3M | $-3.8M | $-3.5M | $1.3M | $-2.4M | — | $-3.1M | $-725028.00 | $-2.4M |
| Returns | |||||||||||||||||
| ROE | -72.1% | -72.1% | -62.8% | -40.3% | -46.8% | -36.6% | -114.3% | -222.5% | -257.5% | -63.2% | -508.0% | -27.3% | -239.6% | 303.6% | 356.2% | -697.3% | -112.6% |
| Valuation | |||||||||||||||||
| P/B | 5.78 | 5.78 | 5.49 | 4.10 | 5.93 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | -77.5% | 206.9% | 20.8% | -96.8% | 152.4% | 843.1% | -58.6% | -6.3% | 37.3% | — |
| EPS Growth | 12.8% | 12.8% | -21.9% | 28.9% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.39 → -0.34
Residual
+5.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.